Corrigendum: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5

In the original article, there were mistakes in Figures 1C, 6C as published. In Figure 1C, the original image of RANKL induced group was mistakenly selected. Figure 1C is now replaced with the right image. In Figure 6C, the original image of OVX group was wrongly selected.Figure 6C is now replaced with the right image. The corrected Figures 1C, 6C appear below.

FIGURE 1.

M54 inhibits RANKL-induced osteoclast differentiation and bone resorption in vitro. (A) Chemical structure of M54 and the synthesis process. (B) Formation of TRAP-positive cells from BMMCs and the quantification of formed osteoclasts. (C) Formation of TRAP-positive cells from RAW264.7 cells and the quantification of formed osteoclasts. (D) The resorption area on the bone biomimetic synthetic surface was quantified by image analysis (^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001).

FIGURE 6.

M54 prevents ovariectomy-induced bone loss in vivo. (A) Representative H&E staining of distal femoral sections and quantification of trabecular area from each group 6 week after the operation (×40). (B) Representative TRAP-stained histologic distal femur sections from sham, OVX and OVX + M54 group (×400). (C) Micro CT analysis of the distal femur from sham, OVX, and OVX + M54 group. (D) Calculations of bone value/total value (BV/TV), trabecular number (Tb.N), bone mineral density (BMD), and bone surface area/total value (BS/TV). (E) Serum TRAcp5B, TNF-α, and IL-6 were examined (^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001).

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.